Welcome to the 3rd issue of the BEAMER project newsletter. Catch up on the latest, including highlights from the project General Assembly, insights on patient adherence in clinical trials, and strategies to boost adherence through understanding human behavior.
BEAMER, which stands for BEhavioral and Adherence Model for improving quality, health outcomes, and cost-Effectiveness of healthcaRe, is a project focused on understanding and enhancing treatment adherence. By leveraging insights from behavioural science, BEAMER aims to develop an open-source model that identifies the key factors influencing treatment adherence. This model will enable the identification of patient subpopulations based on their unique needs, laying the groundwork for tailored solutions to improve adherence behaviour. With collaboration from 27 partners across the healthcare spectrum—including universities, healthcare providers, patient organizations, research and technology firms, nonprofit organizations, and global pharmaceutical companies—This collaborative effort promises to revolutionize adherence support, ensuring that the right patients receive the right support at the right time.
ECHAlliance’s role in BEAMER:
ACKNOWLEDGEMENT & DISCLAIMER: The BEAMER project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Link2Trials. This communication reflects the views of the authors and neither the IMI nor the European Union, EFPIA, or Link2Trials are liable for any use that may be made of the information contained herein.
